Sugammadex + neostigmine

Phase 3Completed

2 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Anesthesia, General

Conditions

Anesthesia, General

Trial Timeline

Nov 10, 2005 → Aug 29, 2006

NCT ID

NCT00451100

About Sugammadex + neostigmine

Sugammadex + neostigmine is a phase 3 stage product being developed by Merck for Anesthesia, General. The current trial status is completed. This product is registered under clinical trial identifier NCT00451100. Target conditions include Anesthesia, General.

What happened to similar drugs?

1 of 20 similar drugs in Anesthesia, General were approved

Approved (1) Terminated (0) Active (19)

✅Fospropofol disodium, propofol + Fospropofol disodium, propofol + Fospropofol disodium, propofolEisaiApproved

🔄Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 3

🔄Ropivacaine + BupivacaineAstraZenecaPhase 3

🔄Sugammadex + Rocuronium + Sevoflurane + PropofolMerckPhase 3

🔄Rocuronium + Sugammadex + Neostigmine + AtropineMerckPhase 3

🔄Rocuronium 0.6 mg/kg intubating dose + Rocuronium 0.9 mg/kg intubating dose + Rocuronium 0.1 mg/kg maintenance dose + Rocuronium 0.15 mg/kg maintenance dose + Rocuronium 0.2 mg/kg maintenance + Vecuronium 0.1 mg/kg intubating dose + Vecuronium 0.025 mg/kg maintenance doseMerckPhase 3

🔄Rocuronium bolus maintenance + rocuronium continuous infusion maintenanceMerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04546672	Approved	Completed	Mar 16, 2021	Aug 13, 2023	Bowel Dysfunction
NCT03276026	Approved	Terminated	Feb 12, 2018	Nov 8, 2018	Postoperative Nausea and Vomiting
NCT03112993	Approved	Completed	May 30, 2017	Aug 14, 2018	Spine Surgery
NCT02861131	Approved	Completed	Jan 24, 2017	Apr 30, 2018	Postoperative Complications
NCT02909439	Approved	Completed	Nov 1, 2016	Feb 1, 2018	Incomplete Reversal of Neuromuscular Block
NCT01050543	Phase 3	Completed	Feb 1, 2010	Aug 20, 2010	Neuromuscular Blockade
NCT00825812	Phase 3	Completed	Jan 1, 2010	Sep 1, 2010	Anesthesia, General
NCT00451217	Phase 3	Completed	Nov 17, 2005	Mar 6, 2006	Anesthesia, General
NCT00451100	Phase 3	Completed	Nov 10, 2005	Aug 29, 2006	Anesthesia, General

Competing Products

20 competing products in Anesthesia, General

See all competitors

Product	Company	Stage	Hype Score
Fospropofol disodium, propofol + Fospropofol disodium, propofol + Fospropofol disodium, propofol	Eisai	Approved	43
arm 1 + LUSEDRA + Propofol (arm 3)	Eisai	Phase 1	29
Remimazolam Tosilate for Injection	Jiangsu Hengrui Medicine	Pre-clinical	26
Remimazolam Tosilate + Propofol	Jiangsu Hengrui Medicine	Phase 3	40
Remimazolam Tosylate	Jiangsu Hengrui Medicine	Phase 1	29
HR020602 injection + fentanyl injection ； remifentanil injection	Jiangsu Hengrui Medicine	Phase 2	35
Remimazolam Tosilate + Propofol	Jiangsu Hengrui Medicine	Phase 2	35
Remimazolam Tosilate + Propofol Injection.	Jiangsu Hengrui Medicine	Phase 2	35
Ropivacaine + Bupivacaine	AstraZeneca	Phase 3	40
Sugammadex	Merck	Phase 2	35
Sugammadex	Merck	Phase 2	35
Sugammadex + Rocuronium + Sevoflurane + Propofol	Merck	Phase 3	40
Rocuronium + Sugammadex + Neostigmine + Atropine	Merck	Phase 3	40
Rocuronium 0.6 mg/kg intubating dose + Rocuronium 0.9 mg/kg intubating dose + Rocuronium 0.1 mg/kg maintenance dose + Rocuronium 0.15 mg/kg maintenance dose + Rocuronium 0.2 mg/kg maintenance + Vecuronium 0.1 mg/kg intubating dose + Vecuronium 0.025 mg/kg maintenance dose	Merck	Phase 3	40
Rocuronium bolus maintenance + rocuronium continuous infusion maintenance	Merck	Phase 3	40
Sugammadex + Rocuronium	Merck	Phase 3	40
Sugammadex + Neostigmine	Merck	Phase 3	40
sugammadex	Merck	Phase 3	40
Sugammadex + Succinylcholine + Rocuronium	Merck	Phase 3	40
Rocuronium bromide + Rocuronium bromide + Rocuronium bromide + Sevoflurane + Propofol	Merck	Phase 3	40